Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
Notes underwriting agrmnt
Allarity Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "FOURTH CERTIFICATE OF AMENDMENT (SERIES A PREFERRED STOCK)"
08/11/2023 8-K Quarterly results
07/27/2023 8-K Resignation/termination of a director, Appointed a new director
Docs: "Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives"
07/17/2023 8-K Other Events  Interactive Data
07/11/2023 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "THIRD CERTIFICATE OF AMENDMENT (SERIES A PREFERRED STOCK)",
"FORM OF AMENDED AND RESTATED COMMON STOCK PURCHASE WARRANT"
07/06/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering BOSTON, MA — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the pricing of its “reasonable best efforts” public offering of 2,444,445 shares of common stock and common warrants to purchase up to 2,444,445 shares of common stock at an effective combined price of $4.50 per share and common warrant for aggregate gross proceeds of approximately $11 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $4.50 per share, will be exercisable immediately and will expire five years from the initial ..."
07/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Initial Data from Allarity’ s Phase 2 Trial of IXEMPRA Indicate Potential for Improved Clinical Benefit in DRP-Selected Metastatic Breast Cancer Patients Boston, MA — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced initial results from its European Phase 2 clinical trial evaluating the efficacy of IXEMPRA ® in metastatic breast cancer patients selected with the DRP-IXEMPRA companion diagnostic candidate. Researchers prescreened mBC patients using Allarity’ s DRP-IXEMPRA CDx, a complex transcriptomic signature comprising multiple mRNA biomarkers of drug response/resistance. Patients were assigned a DRP-score, and those with scores a..."
06/30/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Second Amendment to Certificate of Designation (Series A Preferred Stock)",
"SECURED NOTE PURCHASE AGREEMENT",
"SECURED PROMISSORY NOTE",
"SECURITY AGREEMENT"
06/28/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and ...
Docs: "FOURTH CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF ALLARITY THERAPEUTICS, INC.",
"PRESS RELEASE ANNOUNCING REVERSE STOCK SPLIT"
06/01/2023 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "FIRST CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS OF",
"FIRST AMENDMENT TO THE MODIFICATION AND EXCHANGE AGREEMENT",
"FOURTH AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT"
05/26/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
04/25/2023 8-K Quarterly results
04/19/2023 8-K Quarterly results
03/28/2023 8-K Quarterly results
03/20/2023 8-K Quarterly results
03/20/2023 8-K Quarterly results
03/09/2023 8-K Investor presentation
Docs: "CORPORATE PRESENTATION"
02/28/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "FORM OF SECURITIES PURCHASE AGREEMENT",
"FORM OF REGISTRATION RIGHTS AGREEMENT",
"LIMITED WAIVER AGREEMENT"
02/10/2023 8-K Quarterly results
02/06/2023 8-K Quarterly results
01/23/2023 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Regulation FD Disclosure ...
01/20/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders Boston, MA U.S.A. — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care today announced that the Company’ s 2023 Annual Meeting of Stockholders , on January 19, 2023, at 1:00 p.m. was adjourned without any business being conducted. The Meeting was adjourned until Friday, February 3, 2023, to allow additional time for stockholders to vote on the proposals set forth in the Company’ s definitive proxy statement filed with the U.S. Securities and Exchange Commission on December 6, 2022 . The adjourned Meeting will reconvene on February 3, 2023, at 1:00 p.m. virtually at http..."
01/19/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "EMPLOYMENT AGREEMENT WITH JAMES G. CULLEM DATED JANUARY 12, 2023",
"EMPLOYMENT AGREEMENT WITH JOAN BROWN DATED JANUARY 12, 2023"
01/18/2023 8-K Quarterly results
12/21/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
12/12/2022 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders  Interactive...
12/01/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date"
11/25/2022 8-K Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...
Docs: "CERTIFICATE OF DESIGNATION OF THE SERIES B PREFERRED STOCK",
"SECURED NOTE PURCHASE AGREEMENT",
"SECURITY AGREEMENT",
"SECURED PROMISSORY NOTE"
11/15/2022 8-K Quarterly results
Docs: "Allarity Therapeutics Reports Third Quarter 2022 Financial Results Cambridge, MA U.S.A. — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022. Balance Sheet: As of September 30, 2022, Allarity’ s cash was $3.9 million, as compared to $19.6 million as of December 31, 2021. R&D Expenses: Research and Development expenses were $3.0 million for the three months ended September 30, 2022, as compared to $1.4 million for the three months ended September 30, 2021. G&A Expenses: General and Administrative expenses were $1.6 million for the three months ended September 30, 2022, as c..."
10/14/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
10/11/2022 8-K Quarterly results
Docs: "Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements"
09/30/2022 8-K Quarterly results
09/26/2022 8-K Appointed a new director
Docs: "Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors Cambridge, MA U.S.A. — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced the appointment of Jerry McLaughlin as a new member of its Board of Directors, effective October 1, 2022. Mr. McLaughlin is a highly accomplished biotechnology executive with extensive experience in financing, drug development, licensing, commercialization, and product lifecycle management. Mr. McLaughlin is expected to serve on the compensation, and audit committees as an independent director. “I am delighted that Jerry has chosen to join Allarity’ s board at ...",
"UPDATE TO COMPANY OVERVIEW PRESENTATION"
09/12/2022 8-K Changes in Registrant's Certifying Accountant, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Allarity Therapeutics Announces Appointment of New Auditor Cambridge, MA U.S.A. — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, announced today the appointment of Wolf & Company, P.C. as the Company’ s independent registered public accounting firm effective immediately. The appointment of Wolf & Company has been approved by both the audit committee and the Board of Directors of the Company. The appointment of Wolf & Company has no immediate effect on the Company’ s status as being non-compliant with Nasdaq Listing Rule 5250. However, it is a pivotal part of the Company’ s efforts to regain compliance. Allarity is already working with Wolf & Com..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy